S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

$24.80
+0.25 (+1.02%)
(As of 01:51 PM ET)
Today's Range
$24.09
$24.89
50-Day Range
$16.75
$26.10
52-Week Range
$12.54
$28.91
Volume
99,859 shs
Average Volume
358,626 shs
Market Capitalization
$744.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.88

Bicycle Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
93.0% Upside
$47.88 Price Target
Short Interest
Healthy
8.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Bicycle Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$209,125 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.20) to ($5.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

523rd out of 938 stocks

Pharmaceutical Preparations Industry

245th out of 433 stocks

BCYC stock logo

About Bicycle Therapeutics Stock (NASDAQ:BCYC)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II and phase II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. The company has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC Stock Price History

BCYC Stock News Headlines

AI Bubble Now at Critical Mass
Washington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.
Take a cool bike ride at Icicle Bicycle
BCYC Apr 2024 12.500 call
BCYC Apr 2024 22.500 call
AI Bubble Now at Critical Mass
Washington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.
BCYC Apr 2024 20.000 put
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
BCYC Mar 2024 7.500 put
BCYC Jun 2024 7.500 put
See More Headlines
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BCYC
Fax
N/A
Employees
284
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.88
High Stock Price Target
$65.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+93.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-180,660,000.00
Net Margins
-669.72%
Pretax Margin
-664.32%

Debt

Sales & Book Value

Annual Sales
$26.98 million
Book Value
$12.35 per share

Miscellaneous

Free Float
26,979,000
Market Cap
$744.99 million
Optionable
Optionable
Beta
0.90
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Kevin Lee M.B.A. (Age 56)
    Ph.D., CEO & Executive Director
    Comp: $1.31M
  • Sir Gregory Paul Winter CBE (Age 73)
    FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director
    Comp: $55k
  • Mr. Alistair Milnes (Age 50)
    Chief Operating Officer
    Comp: $796.09k
  • Dr. Michael Skynner B.sc. Ph.d. (Age 54)
    Ph.D., Chief Technology Officer
    Comp: $881.01k
  • Dr. Christian Heinis
    Scientific Founder
  • Ms. Alethia Rene Young (Age 45)
    Chief Financial Officer
  • Mr. Travis Thompson
    Senior VP, Chief Accounting Officer & Principal Accounting Officer
  • Dr. Nicholas Keen Ph.D. (Age 55)
    Chief Scientific Officer
  • Mr. Zafar Qadir
    General Counsel
  • Mr. David E. Borah CFA
    Senior Vice President of Capital Markets & Corporate Communications

BCYC Stock Analysis - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCYC shares.
View BCYC analyst ratings
or view top-rated stocks.

What is Bicycle Therapeutics' stock price target for 2024?

8 brokers have issued 12 month price targets for Bicycle Therapeutics' shares. Their BCYC share price targets range from $32.00 to $65.00. On average, they predict the company's stock price to reach $47.88 in the next year. This suggests a possible upside of 93.0% from the stock's current price.
View analysts price targets for BCYC
or view top-rated stocks among Wall Street analysts.

How have BCYC shares performed in 2024?

Bicycle Therapeutics' stock was trading at $18.08 on January 1st, 2024. Since then, BCYC shares have increased by 37.2% and is now trading at $24.80.
View the best growth stocks for 2024 here
.

When is Bicycle Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BCYC earnings forecast
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings data on Tuesday, February, 20th. The company reported ($1.16) earnings per share for the quarter, topping analysts' consensus estimates of ($1.23) by $0.07. The company earned $5.33 million during the quarter, compared to the consensus estimate of $11.68 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 57.80% and a negative net margin of 669.72%.

What ETFs hold Bicycle Therapeutics' stock?

ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX),

What other stocks do shareholders of Bicycle Therapeutics own?
When did Bicycle Therapeutics IPO?

Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (5.16%), Armistice Capital LLC (5.11%), Westfield Capital Management Co. LP (3.05%), Verition Fund Management LLC (2.47%), Platinum Investment Management Ltd. (1.21%) and Parkman Healthcare Partners LLC (1.04%). Insiders that own company stock include Alistair Milnes, Kate Bingham, Kevin Lee, Lee Kalowski, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Stephen B Alexander and Travis Alvin Thompson.
View institutional ownership trends
.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCYC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners